December 13, 2017 (Medical News Today) Lung cancer is the most common cause of cancer-related deaths worldwide. It is the second most common cancer among men and women in the …
Cancer: Some immune cells found to give tumors a helping hand Read More
October 12, 2017 (HealthDay News) Patients with severe neurotoxicity after infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have evidence of endothelial activation, according to a study published online …
Neurotoxicity Characterized After Infusion of CD19 CAR-T Cells Read More
January 31, 2018 (HealthDay News) Single infusion provided durable remission with long-term persistence in pediatric, young adult patients A single infusion of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, …
Tisagenlecleucel Beneficial for Youth With Refractory B-Cell ALL Read More
Here are some links to studies that have recently come out on CAR T-Cell. These are obtainable only by a paid subscription to the journal. March 2018 Apoptotic Cells Dramatically …
Other Studies on CAR T-Cell Therapy Read More
December 11, 2017 (HealthDay News) Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and …
ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas Read More
T-Cell Receptor Therapy: The Next Generation T cells are one type of lymphocyte important for the immune system to function properly. As with CAR T-cell therapy effect on hematologic cancers, …
CAR T-Cell Therapy HCP Guide – The Next Generation for T-Cell Receptor Therapy Read More
The Challenging Solid Tumor Microenvironment The challenging tumor microenvironment is another obstacle with CAR T-cell therapy of solid tumors. As reported by Newick and colleagues, significant hurdles include: Trafficking: CAR …
CAR T-Cell Therapy HCP Guide – Challenges: Car-T and Solid Tumors Read More
October 19, 2017 (Medical News Today) Immunotherapy, which activates a patient’s own immune system to attack cancer, is still a new approach to treating cancer. Researchers from the Massachusetts Institute …
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy Read More
Solid Tumor Research: Ongoing CAR T-cell therapy has shown great success in hematologic malignancies, such as non-Hodgkin’s lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma), acute lymphoblastic leukemia (ALL), chronic …
CAR T-Cell Therapy HCP Guide – Solid Tumors Read More
ZUMA-3 and ZUMA-4 Trials In addition to the October 2017 approval for Non-Hodgkin lymphoma, Yescarta (axicabtagene ciloleucel) has shown impressive early results in difficult-to-treat patients with ALL. As reported in …
CAR T-Cell Therapy HCP Guide – Efficacy and Safety of Zuma Trials Read More